Biovica International
1,2
SEK
Mindre end 1K følgere
BIOVIC B
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Finansielt overblik og estimater
Ownership
-21,98%
-40,3%
-40%
-47,25%
-56,44%
-53,67%
-94,96%
-86,89%
-89,21%
Biovica International is a pharmaceutical company that focuses its research on cancer treatments. The company is developing methods for measuring cell proliferation, where the test is taken via blood samples. The tests analyze the risk for the development of the enzyme thymidine kinase, an enzyme that is linked to tumor growth. The main area of focus is within treatment of breast cancer. The company was founded in 2008 and is headquartered in Uppsala.
Læs mereMarkedsværdi
117,34 mio. SEK
Aktieomsætning
-
Omsætning
7,29 mio.
EBIT %
-1.740,05 %
P/E
-
Udbytteafkast, %
-
Finanskalender
18.6
2025
Årsrapport '25
11.9
2025
Delårsrapport Q1'26
16.9
2025
Generalforsamling '25
Alle
Selskabspræsentationer
Selskabsmeddelelser
Eksterne analyser
ViserAlle indholdstyper
Biovica Q3 Interim report Nov 2024 - Jan 2025
Biovica and Outcomes4Me Partner to Support Metastatic Breast Cancer Patients to Better Understand the Effectiveness of their Treatment
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools